These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours. Jackman AL, Melin CJ, Kimbell R, Brunton L, Aherne GW, Theti DS, Walton M. Biochim Biophys Acta; 2002 Jul 18; 1587(2-3):215-23. PubMed ID: 12084463 [Abstract] [Full Text] [Related]
6. Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer. Shen J, Wei J, Guan W, Wang H, Ding Y, Qian X, Yu L, Zou Z, Xie L, Costa C, Bivona T, Rosell R, Liu B. J Transl Med; 2014 Dec 14; 12():355. PubMed ID: 25496700 [Abstract] [Full Text] [Related]
7. A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance. Berg RW, Ferguson PJ, Vincent MD, Koropatnick DJ. Cancer Gene Ther; 2003 Apr 14; 10(4):278-86. PubMed ID: 12679800 [Abstract] [Full Text] [Related]
9. Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331. Ford HE, Mitchell F, Cunningham D, Farrugia DC, Hill ME, Rees C, Calvert AH, Judson IR, Jackman AL. Clin Cancer Res; 2002 Jan 14; 8(1):103-9. PubMed ID: 11801545 [Abstract] [Full Text] [Related]
10. Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer. Ishida Y, Kawakami K, Tanaka Y, Kanehira E, Omura K, Watanabe G. Anticancer Res; 2002 Jan 14; 22(5):2805-9. PubMed ID: 12530000 [Abstract] [Full Text] [Related]
11. Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed. Avallone A, Di Gennaro E, Silvestro L, Iaffaioli VR, Budillon A. Expert Opin Drug Saf; 2014 Jan 14; 13(1):113-29. PubMed ID: 24093908 [Abstract] [Full Text] [Related]
12. Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Takechi T, Okabe H, Fukushima M, Kitajima M. Anticancer Res; 1999 Jan 14; 19(6C):5635-40. PubMed ID: 10697632 [Abstract] [Full Text] [Related]
13. Association of gastric and intestinal phenotypic marker expression of gastric carcinomas with tumor thymidylate synthase expression and response to postoperative chemotherapy with 5-fluorouracil. Tajima Y, Shimoda T, Nakanishi Y, Yokoyama N, Tanaka T, Shimizu K, Saito T, Kawamura M, Kusano M, Kumagai K. J Cancer Res Clin Oncol; 2003 Dec 14; 129(12):683-90. PubMed ID: 14576935 [Abstract] [Full Text] [Related]
14. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L. Cancer Res; 1995 Apr 01; 55(7):1407-12. PubMed ID: 7882343 [Abstract] [Full Text] [Related]
15. Raltitrexed (Tomudex): an alternative choice in patients intolerant to 5-fluorouracil. Kempin S, Gutierrez J, Wilson E, Lowery C, Diasio R. Cancer Invest; 2002 Apr 01; 20(7-8):992-5. PubMed ID: 12449732 [Abstract] [Full Text] [Related]
16. The discrepancy in thymidylate synthase and dihydropyrimidine dehydrogenase expression depending on measurement methodologies in stage 4 gastric cancer. Akamoto S, Usuki H, Haba R, Kakinoki K, Okano K, Izuishi K, Wakabayashi H, Suzuki Y. Hepatogastroenterology; 2008 Apr 01; 55(86-87):1882-6. PubMed ID: 19102414 [Abstract] [Full Text] [Related]
17. Correlation between thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level and in vitro chemosensitivity to 5-fluorouracil, in relation to differentiation in gastric cancer. Fakhrejahani E, Miyamoto A, Tanigawa N. Cancer Chemother Pharmacol; 2007 Aug 01; 60(3):437-46. PubMed ID: 17377791 [Abstract] [Full Text] [Related]
18. A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors. Grem JL, Sorensen JM, Cullen E, Takimoto CH, Steinberg SM, Chen AP, Hamilton JM, Arbuck SG, McAtee N, Lawrence D, Goldspiel B, Johnston PG, Allegra CJ. Clin Cancer Res; 1999 Sep 01; 5(9):2381-91. PubMed ID: 10499608 [Abstract] [Full Text] [Related]
19. Raltitrexed, a novel folate-based thymidylate synthase inhibitor, for the treatment of acute leukemia: is this drug active against acute myelogenous leukemia? Takemura Y, Kobayashi H, Miyachi H. Int J Hematol; 2000 Jul 01; 72(1):112-4. PubMed ID: 10979221 [No Abstract] [Full Text] [Related]
20. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Ichikawa W, Uetake H, Shirota Y, Yamada H, Nishi N, Nihei Z, Sugihara K, Hirayama R. Clin Cancer Res; 2003 Feb 01; 9(2):786-91. PubMed ID: 12576451 [Abstract] [Full Text] [Related] Page: [Next] [New Search]